Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with myeloma (a type of blood cancer) and have already completed a standard first-line treatment to reduce the cancer. People who needed extra treatment because their myeloma did not respond initially may also be considered.
- People whose doctors consider them well enough to go through a stem cell transplant with high-dose chemotherapy as the next step in their treatment.
- People who are between 18 and 75 years of age.
- People whose general physical ability to carry out daily activities meets a certain minimum level (measured by a standard medical scale called ECOG — confirm with trial site).
- People whose kidneys are working well enough, measured by a specific blood filtering rate (confirm with trial site).
- People whose heart is pumping strongly enough, based on a heart scan taken within the three months before the trial treatment begins (confirm with trial site).
- People who have given their written agreement to take part in the trial voluntarily.
Who may not be able to join:
- People who have an active infection that is not currently under control.
- People whose overall health burden related to a transplant is assessed as too high, based on a standard scoring system called the transplantation comorbidity index (confirm with trial site).
- People who currently have another active cancer, with the exception of certain early-stage or low-risk skin, cervical, or prostate cancers. People who were previously treated for another cancer must have finished that treatment at least six months before registering, with no signs of that cancer being active since then.
- People who have a significant problem with blood clotting or a bleeding disorder.
- People who have other medical conditions that could interfere with completing the trial treatment, affect how well the treatment is tolerated, or slow down recovery.
- People who are unwilling or unable to cooperate with the requirements of the trial treatment plan.
- People who are pregnant or breastfeeding. People of childbearing potential who are not willing to use adequate contraception (such as hormonal methods, an intrauterine device, or latex condoms) during the trial treatment and for 12 months after it ends.
- People who have taken any experimental anti-cancer treatment within 14 days before the expected start of the trial treatment.
- People who have a known allergy or medical reason that prevents them from receiving any of the chemotherapy drugs used in this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Thomas Pabst, Prof Dr. med, Department for Medical Oncology; University Hospital/Inselspital
Phone: +41 31 632 84 30
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete Remission (CR) Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.